

Special Issue

Rheumatology Diseases: Advances in the Understanding of Pathogenesis, Biomarker Research and Treatment Target

Message from the Guest Editor

Autoimmune rheumatic diseases (AIRDs) are chronic, systemic diseases characterized by unknown etiology and pathogenesis. Recent studies have revealed the multifactorial basis of AIRD with the leading role of genetic and epigenetic factors as well as environmental factors in disease predisposition, onset and progression. Epigenetic factors, including DNA methylation, histone modifications and deregulated miRNA expression in circulation, in addition to local expression, play an important role in the pathogenesis of AIRD by regulating key biological pathways. The recent advances in our understanding of the pathogenesis of AIRD enable the development of effective therapeutic agents, including biological and target therapies minimizing the side-effects of non-selective immunosuppressive agents. Recent studies have shown the effects of new therapeutic strategies, including the use of CAR-T cell therapies, and Bi-specific T-cell engagers, in rheumatology clinical practice, which could allow us to revolutionize the treatment approach in this type of autoimmune diseases.

Guest Editor

Dr. Russka Shumnalieva

1. Department of Rheumatology, Clinic of Rheumatology, University Hospital St. "Ivan Rilski", Medical University of Sofia, 13 Urvich St., 1612 Sofia, Bulgaria
2. Medical Faculty, Sofia University "St. Kliment Ohridski", 1407 Sofia, Bulgaria

Deadline for manuscript submissions

closed (31 July 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9

CiteScore 6.8

Indexed in PubMed



mdpi.com/si/210134

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).